Mark M. Sieczkarek.
​
EMERYVILLE, Calif.—NovaBay Pharmaceuticals (NYSE MKT: NBY), has appointed Mark M. Sieczkarek as president and chief executive officer, effective June 13. Sieczkarek has been a NovaBay director since January 2014, was named chairman in April 2015 and has served as interim president and CEO since November 2015. He has been instrumental in the development and implementation of the go-to-market strategy for Avenova, the company’s proprietary lid and lash cleaner.

Sieczkarek previously was CEO of Solta Medical (acquired by Valeant Pharmaceuticals) and of Conceptus (acquired by Bayer HealthCare). Prior to that, he was senior vice president and president of the Americas and Europe for Bausch + Lomb (acquired by Valeant Pharmaceuticals), where he was responsible for overseeing multinational commercial launches of several leading products.